C-reactive protein as a predictor of improvement and readmission in heart failure

European Journal of Heart Failure

Volumn 4, Issue 3, 2002, Pages 331-336

  Alonso Martinez J L ^a   Llorente Diez, B ^a   Echegaray Agara, M ^a   Olaz Preciado, F ^a   Urbieta Echezarreta, M ^a   Gonzalez Arencibia C ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

C reactive protein; Chronic inflammatory response; Heart failure

Indexed keywords

C REACTIVE PROTEIN;

AGED; ANALYSIS OF VARIANCE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODYNAMIC MONITORING; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SYNCOPE; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT INDICATION;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INFLAMMATION; MALE; PATIENT READMISSION; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC; STROKE VOLUME;

EID: 0036623813     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00021-1     Document Type: Article

References (28)

1. Osmand AP, Friedenson B, Gewurz H, Painter RH, Hofmann T, Shelton E. Characterization of C-reactive protein and the complement subcomplement Clt as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci USA 1977;74:739-43.
2. Whitehead AS, Bruns GAP, Markham AF, Colten HR, Woods DE. Isolation of human C-reactive protein complementary DNA and localization of the gene to chromosome 1. Science 1983;221:69-71.
3. Volanakis JE, Xu Y, Macon KJ. Human C-reactive protein and host defense. In: Marchalonis JJ, Reinsch CL, editors. Defense molecules. Wiley Liss: New York, 1990. p. 161-75.
4. Ballou SP, Kushner I. C-reactive protein ant the acute phase response. Adv Intern Med 1992;37:313-36.
5. Kushner I, Kaplan MH. Studies of acute phase protein. I. An immunohistochemical method for the localization of Cx-reactive protein in rabbits. Association with necrosis in local inflammatory lesions. J Exp Med 1961;114:961-74.
6. Zanedi K, Mortensen RF. Macrophage tumoricidal activity induced by human C-reactive protein. Cancer Res 1986;46:5077-83.
7. Barna BP, Thomassen MJ, Clements M, et al. Cytoquine induction associated with human C-reactive protein. Fed Am Soc Exp Biol J 1989;3:A284.
8. Vetter ML, Gewurz H, Hansen B, James K, Baum LL. Effects of C-reactive protein on human lymphocyte responsiveness. J Immunol 1983;130:2121-6.
9. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956-63.
10. Riker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999;130:933-7.
11. Oparil S, Oberman A. Nontraditional cardiovascular risk factors. Am J Med Sci 1999;317:193-207.
12. Chen YT, Vaccarino V, Wililiams CS, Butler J, Berkman LF, Krumholz HM. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med 1999;106:605-12.
13. Smith WM. Epidemiology of congestive heart failure. Am J Cardiol 1985;55:3A-8A.
14. Senni M, Tribouilley CM, Rodeheffer RJ, et al. Congestive heart failure in community. Trends in incidence and survival in a 10-year period. Arch Intern Med 1999;159:29-34.
15. National Heart, Lung and Blood Institute. Congestive heart failure in the United States. A new epidemic. Bethesda, MD: US Department of Health and Human Services, 1996.
16. The CONSENSUS trial Study Group. Effects of Enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987;316:1429-35.
17. SOLVD Investigators. Effect of Enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;325:293-302.
18. Packer M, Bristow MR, Cohn JN, et al. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
19. Pitt B, Zannad F, Remme WJ, et al. The effect of Spirolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
20. Werdan K. The activated immune system in congestive heart failure. From dropsy to the cytokine paradigm. J Intern Med 1998;243:87-92.
21. Samsonov M, Lopatin J, Tiltz GP. The activated immune system an the renin-angiotensin-aldosterone system in congestive heart failure. J Intern Med 1998;243:93-8.
22. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995;92:1479-86.
23. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997;79:1128-31.
24. European Study Group on Diastolic Heart Failure. Working Group Report. How to diagnose diastolic heart failure. Eur Heart J 1998;19:990-1003.
25. Cohn JN. The management of chronic heart failure. N Engl J Med 1996;335:490-8.
26. Grupta S, Leatham EW, Carrington DL, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azythromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
27. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of Roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. ROXIS study group. Lancet 1997;350:404-7.
28. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106:506-12.